XGN - Exagen highlights promising data from AVISE lupus test study

Exagen (XGN) announces that its lupus test showed promise in a multi-center study in patients suspected of the disease.AVISE lupus test showed "statistically significant" clinical utility in achieving a definitive SLE Diagnosis and positively impacts treatment decisions, the company said.The study showed that the test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus ((SLE)) in patients suspected of the disease and informed appropriate treatment decisions.Assessment of the confidence in the diagnosis of SLE and initiation of hydroxychloroquine ((HCQ)) showed that the test impacted physician behavior, the company said.The study results were published in Lupus & Science Medicine.

For further details see:

Exagen highlights promising data from AVISE lupus test study